EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 52011XC1028(03)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2011 to 31 August 2011 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2011 to 31 August 2011 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2011 to 31 August 2011 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
OJ C 316, 28.10.2011, p. 1–17
(BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
28.10.2011 |
EN |
Official Journal of the European Union |
C 316/1 |
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2011 to 31 August 2011
(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) )
2011/C 316/01
— Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
||
|
13.7.2011 |
Benlysta |
belimumab |
|
EU/1/11/700/001-002 |
powder for concentrate for solution for infusion |
L04AA26 |
15.7.2011 |
||
|
13.7.2011 |
Temozolomide Sun |
temozolomide |
|
EU/1/11/697/001-012 |
Capsule, hard |
L01AX03 |
18.7.2011 |
||
|
13.7.2011 |
Xgeva |
denosumab |
|
EU/1/11/703/001-002 |
Solution for injection |
M05BX04 |
15.7.2011 |
||
|
13.7.2011 |
Yervoy |
ipilimumab |
|
EU/1/11/698/001-002 |
Concentrate for solution for infusion |
L01XC11 |
15.7.2011 |
||
|
18.7.2011 |
Victrelis |
boceprevir |
|
EU/1/11/704/001 |
Capsule, hard |
J05AE |
20.7.2011 |
||
|
20.7.2011 |
Fampyra |
fampridine |
|
EU/1/11/699/001-002 |
Prolonged-release tablet |
N07XX07 |
25.7.2011 |
||
|
20.7.2011 |
TOBI Podhaler |
Tobramycin |
|
EU/1/10/652/001-003 |
Inhalation powder, hard capsule |
J01GB01 |
25.7.2011 |
||
|
26.7.2011 |
Ibandronic acid Sandoz |
Ibandronic acid |
|
EU/1/11/685/001-005 |
Film-coated tablet |
M05BA06 |
28.7.2011 |
||
|
27.7.2011 |
Zoely |
nomegestrol/estradiol |
|
EU/1/11/690/001-002 |
Film-coated tablet |
G03AA14 |
1.8.2011 |
||
|
18.8.2011 |
Entacapone Orion |
entacapone |
|
EU/1/11/708/001-004 |
Film-coated tablet |
N04BX02 |
22.8.2011 |
||
|
24.8.2011 |
Levodopa/Carbidopa/Entacapone Orion |
Levodopa, carbidopa, entacapone |
|
EU/1/11/706/001-033 |
Film-coated tablet |
N04BA03 |
29.8.2011 |
||
|
24.8.2011 |
Trajenta |
linagliptin |
|
EU/1/11/707/001-011 |
Film-coated tablet |
A10BH05 |
30.8.2011 |
||
|
26.8.2011 |
Levetiracetam ratiopharm |
levetiracetam |
|
EU/1/11/702/001-031 |
Film-coated tablet Oral solution |
N03AX14 |
31.8.2011 |
||
|
26.8.2011 |
Levetiracetam Teva |
levetiracetam |
|
EU/1/11/701/001-028 |
Film-coated tablet |
N03AX14 |
31.8.2011 |
— Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
||
|
5.7.2011 |
Irbesartan Winthrop |
|
EU/1/06/376/001-033 |
7.7.2011 |
||
|
5.7.2011 |
Relistor |
|
EU/1/08/463/001-011 |
7.7.2011 |
||
|
7.7.2011 |
Adrovance |
|
EU/1/06/364/005 EU/1/06/364/009 |
11.7.2011 |
||
|
7.7.2011 |
Ammonaps |
|
EU/1/99/120/001-004 |
12.7.2011 |
||
|
7.7.2011 |
Hirobriz Breezhaler |
|
EU/1/09/594/001-010 |
11.7.2011 |
||
|
7.7.2011 |
Modigraf |
|
EU/1/09/523/001-002 |
11.7.2011 |
||
|
7.7.2011 |
Removab |
|
EU/1/09/512/001-002 |
11.7.2011 |
||
|
11.7.2011 |
NovoRapid |
|
EU/1/99/119/001 EU/1/99/119/003 EU/1/99/119/005-015 EU/1/99/119/017-023 |
13.7.2011 |
||
|
11.7.2011 |
Onbrez Breezhaler |
|
EU/1/09/593/001-010 |
13.7.2011 |
||
|
11.7.2011 |
Optaflu |
|
EU/1/07/394/001-009 |
13.7.2011 |
||
|
13.7.2011 |
Sildenafil ratiopharm |
|
EU/1/09/603/001-015 |
18.7.2011 |
||
|
13.7.2011 |
Stocrin |
|
EU/1/99/111/001-005 EU/1/99/111/008-011 |
18.7.2011 |
||
|
13.7.2011 |
Sustiva |
|
EU/1/99/110/001-005 EU/1/99/110/008-010 |
18.7.2011 |
||
|
13.7.2011 |
ViraferonPeg |
|
EU/1/00/132/001-050 |
18.7.2011 |
||
|
13.7.2011 |
Viread |
|
EU/1/01/200/001-002 |
18.7.2011 |
||
|
18.7.2011 |
Crixivan |
|
EU/1/96/024/001-005 EU/1/96/024/010 |
20.7.2011 |
||
|
18.7.2011 |
Intrinsa |
|
EU/1/06/352/001-003 |
20.7.2011 |
||
|
18.7.2011 |
Livensa |
|
EU/1/06/351/001-003 |
20.7.2011 |
||
|
18.7.2011 |
Multaq |
|
EU/1/09/591/001-004 |
20.7.2011 |
||
|
18.7.2011 |
ReFacto AF |
|
EU/1/99/103/001-008 |
20.7.2011 |
||
|
18.7.2011 |
Savene |
|
EU/1/06/350/001 |
20.7.2011 |
||
|
20.7.2011 |
Atriance |
|
EU/1/07/403/001 |
25.7.2011 |
||
|
20.7.2011 |
Betaferon |
|
EU/1/95/003/003-012 |
25.7.2011 |
||
|
20.7.2011 |
Esbriet |
|
EU/1/11/667/001-003 |
26.7.2011 |
||
|
20.7.2011 |
Intelence |
|
EU/1/08/468/001 |
25.7.2011 |
||
|
20.7.2011 |
Ratiograstim |
|
EU/1/08/444/001-012 |
25.7.2011 |
||
|
20.7.2011 |
Rivastigmine 1 A Pharma |
|
EU/1/09/585/001-018 |
25.7.2011 |
||
|
20.7.2011 |
Rivastigmine Sandoz |
|
EU/1/09/599/001-018 |
25.7.2011 |
||
|
20.7.2011 |
Silgard |
|
EU/1/06/358/001-008 EU/1/06/358/018-021 |
25.7.2011 |
||
|
20.7.2011 |
Zalasta |
|
EU/1/07/415/001-056 |
25.7.2011 |
||
|
26.7.2011 |
Avaglim |
|
EU/1/06/349/001-010 |
28.7.2011 |
||
|
26.7.2011 |
Bondronat |
|
EU/1/96/012/004 EU/1/96/012/009-013 |
28.7.2011 |
||
|
26.7.2011 |
Busilvex |
|
EU/1/03/254/002 |
28.7.2011 |
||
|
26.7.2011 |
Cymbalta |
|
EU/1/04/296/001-009 |
28.7.2011 |
||
|
26.7.2011 |
Forsteo |
|
EU/1/03/247/001-002 |
28.7.2011 |
||
|
26.7.2011 |
Infanrix hexa |
|
EU/1/00/152/001-008 EU/1/00/152/019-020 |
28.7.2011 |
||
|
26.7.2011 |
Kuvan |
|
EU/1/08/481/001-003 |
28.7.2011 |
||
|
26.7.2011 |
Menveo |
|
EU/1/10/614/001-003 |
28.7.2011 |
||
|
26.7.2011 |
Remicade |
|
EU/1/99/116/001-005 |
28.7.2011 |
||
|
26.7.2011 |
Retacrit |
|
EU/1/07/431/001-025 |
28.7.2011 |
||
|
26.7.2011 |
Stelara |
|
EU/1/08/494/001-004 |
28.7.2011 |
||
|
26.7.2011 |
Xeristar |
|
EU/1/04/297/001-008 |
28.7.2011 |
||
|
27.7.2011 |
Avastin |
|
EU/1/04/300/001-002 |
2.8.2011 |
||
|
27.7.2011 |
Beromun |
|
EU/1/99/097/001 |
1.8.2011 |
||
|
27.7.2011 |
Bondenza |
|
EU/1/03/266/003-006 |
29.7.2011 |
||
|
27.7.2011 |
Bonviva |
|
EU/1/03/265/003-006 |
29.7.2011 |
||
|
27.7.2011 |
Copalia |
|
EU/1/06/372/001-039 |
1.8.2011 |
||
|
27.7.2011 |
Dafiro |
|
EU/1/06/371/001-039 |
1.8.2011 |
||
|
27.7.2011 |
Ecalta |
|
EU/1/07/416/001-002 |
29.7.2011 |
||
|
27.7.2011 |
Emtriva |
|
EU/1/03/261/001-003 |
3.8.2011 |
||
|
27.7.2011 |
Eporatio |
|
EU/1/09/573/001-028 |
29.7.2011 |
||
|
27.7.2011 |
Exforge |
|
EU/1/06/370/001-039 |
29.7.2011 |
||
|
27.7.2011 |
Exjade |
|
EU/1/06/356/001-009 |
1.8.2011 |
||
|
27.7.2011 |
Faslodex |
|
EU/1/03/269/001-002 |
1.8.2011 |
||
|
27.7.2011 |
Fosavance |
|
EU/1/05/310/005 EU/1/05/310/009 |
29.7.2011 |
||
|
27.7.2011 |
Gardasil |
|
EU/1/06/357/001-008 EU/1/06/357/018-021 |
29.7.2011 |
||
|
27.7.2011 |
Imprida |
|
EU/1/06/373/001-039 |
29.7.2011 |
||
|
27.7.2011 |
Integrilin |
|
EU/1/99/109/001-002 |
1.8.2011 |
||
|
27.7.2011 |
Kiovig |
|
EU/1/05/329/001-006 |
29.7.2011 |
||
|
27.7.2011 |
Leflunomide Winthrop |
|
EU/1/09/604/001-010 |
2.8.2011 |
||
|
27.7.2011 |
Nevanac |
|
EU/1/07/433/001 |
29.7.2011 |
||
|
27.7.2011 |
PhotoBarr |
|
EU/1/04/272/001-002 |
2.8.2011 |
||
|
27.7.2011 |
PREZISTA |
|
EU/1/06/380/001-005 |
2.8.2011 |
||
|
27.7.2011 |
Rapamune |
|
EU/1/01/171/001 EU/1/01/171/007-010 EU/1/01/171/013-014 |
1.8.2011 |
||
|
27.7.2011 |
Relistor |
|
EU/1/08/463/001-011 |
1.8.2011 |
||
|
27.7.2011 |
Silgard |
|
EU/1/06/358/001-021 |
2.8.2011 |
||
|
27.7.2011 |
Sycrest |
|
EU/1/10/640/001-006 |
2.8.2011 |
||
|
27.7.2011 |
Thymanax |
|
EU/1/08/498/001-008 |
29.7.2011 |
||
|
27.7.2011 |
Truvada |
|
EU/1/04/305/001-002 |
3.8.2011 |
||
|
27.7.2011 |
Valdoxan |
|
EU/1/08/499/001-008 |
1.8.2011 |
||
|
27.7.2011 |
Vantavo |
|
EU/1/09/572/005 EU/1/09/572/009 |
1.8.2011 |
||
|
27.7.2011 |
Yentreve |
|
EU/1/04/280/001-008 |
29.7.2011 |
||
|
1.8.2011 |
alli |
|
EU/1/07/401/007-016 |
3.8.2011 |
||
|
1.8.2011 |
Doribax |
|
EU/1/08/467/001-002 |
3.8.2011 |
||
|
1.8.2011 |
Gardasil |
|
EU/1/06/357/001-021 |
3.8.2011 |
||
|
1.8.2011 |
Iressa |
|
EU/1/09/526/001-002 |
3.8.2011 |
||
|
1.8.2011 |
Nexavar |
|
EU/1/06/342/001 |
2.8.2011 |
||
|
1.8.2011 |
Pradaxa |
|
EU/1/08/442/001-014 |
3.8.2011 |
||
|
1.8.2011 |
Rivastigmine Teva |
|
EU/1/09/513/001-020 |
3.8.2011 |
||
|
1.8.2011 |
RoActemra |
|
EU/1/08/492/001-006 |
3.8.2011 |
||
|
5.8.2011 |
ATryn |
|
EU/1/06/355/001-003 |
10.8.2011 |
||
|
5.8.2011 |
Biograstim |
|
EU/1/08/450/001-010 |
10.8.2011 |
||
|
5.8.2011 |
Biopoin |
|
EU/1/09/565/001-028 |
10.8.2011 |
||
|
5.8.2011 |
Enbrel |
|
EU/1/99/126/001-022 |
10.8.2011 |
||
|
5.8.2011 |
Focetria |
|
EU/1/07/385/001-002 EU/1/07/385/004 |
10.8.2011 |
||
|
5.8.2011 |
Hepsera |
|
EU/1/03/251/001-002 |
10.8.2011 |
||
|
5.8.2011 |
Hycamtin |
|
EU/1/96/027/001 EU/1/96/027/003-007 |
10.8.2011 |
||
|
5.8.2011 |
InductOs |
|
EU/1/02/226/001 |
10.8.2011 |
||
|
5.8.2011 |
Silapo |
|
EU/1/07/432/001-022 |
10.8.2011 |
||
|
5.8.2011 |
Synflorix |
|
EU/1/09/508/001-010 |
10.8.2011 |
||
|
5.8.2011 |
Viread |
|
EU/1/01/200/001-002 |
10.8.2011 |
||
|
10.8.2011 |
Arava |
|
EU/1/99/118/001-010 |
12.8.2011 |
||
|
10.8.2011 |
Cholestagel |
|
EU/1/03/268/001-004 |
12.8.2011 |
||
|
10.8.2011 |
Filgrastim Hexal |
|
EU/1/08/496/001-016 |
12.8.2011 |
||
|
10.8.2011 |
Lantus |
|
EU/1/00/134/001-037 |
12.8.2011 |
||
|
10.8.2011 |
Optisulin |
|
EU/1/00/133/001-032 |
12.8.2011 |
||
|
10.8.2011 |
Oslif Breezhaler |
|
EU/1/09/586/001-010 |
12.8.2011 |
||
|
10.8.2011 |
Vidaza |
|
EU/1/08/488/001 |
12.8.2011 |
||
|
10.8.2011 |
Zarzio |
|
EU/1/08/495/001-016 |
12.8.2011 |
||
|
18.8.2011 |
Ariclaim |
|
EU/1/04/283/008-012 |
22.8.2011 |
||
|
18.8.2011 |
Karvezide |
|
EU/1/98/085/001-034 |
22.8.2011 |
||
|
18.8.2011 |
Osseor |
|
EU/1/04/287/001-006 |
22.8.2011 |
||
|
18.8.2011 |
Pandemrix |
|
EU/1/08/452/001 |
22.8.2011 |
||
|
18.8.2011 |
Protelos |
|
EU/1/04/288/001-006 |
22.8.2011 |
||
|
18.8.2011 |
Sutent |
|
EU/1/06/347/001-008 |
22.8.2011 |
||
|
18.8.2011 |
Volibris |
|
EU/1/08/451/001-004 |
22.8.2011 |
||
|
19.8.2011 |
Atripla |
|
EU/1/07/430/001-002 |
23.8.2011 |
||
|
24.8.2011 |
Afinitor |
|
EU/1/09/538/001-008 |
30.8.2011 |
||
|
24.8.2011 |
Efficib |
|
EU/1/08/457/001-016 |
30.8.2011 |
||
|
24.8.2011 |
Enbrel |
|
EU/1/99/126/001-022 |
9.9.2011 |
||
|
24.8.2011 |
Intelence |
|
EU/1/08/468/001 |
30.8.2011 |
||
|
24.8.2011 |
IntronA |
|
EU/1/99/127/011-039 EU/1/99/127/041-044 |
30.8.2011 |
||
|
24.8.2011 |
Janumet |
|
EU/1/08/455/001-016 |
30.8.2011 |
||
|
24.8.2011 |
Januvia |
|
EU/1/07/383/001-018 |
30.8.2011 |
||
|
24.8.2011 |
Kentera |
|
EU/1/03/270/001-005 |
30.8.2011 |
||
|
24.8.2011 |
Lantus |
|
EU/1/00/134/001-037 |
30.8.2011 |
||
|
24.8.2011 |
Mepact |
|
EU/1/08/502/001 |
30.8.2011 |
||
|
24.8.2011 |
Micardis |
|
EU/1/98/090/017-022 |
29.8.2011 |
||
|
24.8.2011 |
Modigraf |
|
EU/1/09/523/001-002 |
29.8.2011 |
||
|
24.8.2011 |
Multaq |
|
EU/1/09/591/001-004 |
26.8.2011 |
||
|
24.8.2011 |
Mycamine |
|
EU/1/08/448/001-002 |
26.8.2011 |
||
|
24.8.2011 |
Neupro |
|
EU/1/05/331/001-055 |
26.8.2011 |
||
|
24.8.2011 |
Nplate |
|
EU/1/08/497/001-008 |
30.8.2011 |
||
|
24.8.2011 |
Optisulin |
|
EU/1/00/133/001-032 |
29.8.2011 |
||
|
24.8.2011 |
Osigraft |
|
EU/1/01/179/001 |
30.8.2011 |
||
|
24.8.2011 |
PegIntron |
|
EU/1/00/131/001-050 |
26.8.2011 |
||
|
24.8.2011 |
Pelzont |
|
EU/1/08/460/001-014 |
26.8.2011 |
||
|
24.8.2011 |
Rebetol |
|
EU/1/99/107/001-005 |
29.8.2011 |
||
|
24.8.2011 |
Reyataz |
|
EU/1/03/267/001-010 |
30.8.2011 |
||
|
24.8.2011 |
Ristaben |
|
EU/1/10/621/001-018 |
30.8.2011 |
||
|
24.8.2011 |
Ristfor |
|
EU/1/10/620/001-016 |
30.8.2011 |
||
|
24.8.2011 |
Stalevo |
|
EU/1/03/260/001-038 |
30.8.2011 |
||
|
24.8.2011 |
Starlix |
|
EU/1/01/174/001-021 |
30.8.2011 |
||
|
24.8.2011 |
Tarceva |
|
EU/1/05/311/001-003 |
26.8.2011 |
||
|
24.8.2011 |
Tesavel |
|
EU/1/07/435/001-018 |
30.8.2011 |
||
|
24.8.2011 |
Thyrogen |
|
EU/1/99/122/001-002 |
30.8.2011 |
||
|
24.8.2011 |
Tredaptive |
|
EU/1/08/459/001-014 |
30.8.2011 |
||
|
24.8.2011 |
Trevaclyn |
|
EU/1/08/458/001-014 |
30.8.2011 |
||
|
24.8.2011 |
Tygacil |
|
EU/1/06/336/001 |
30.8.2011 |
||
|
24.8.2011 |
VELCADE |
|
EU/1/04/274/001-002 |
30.8.2011 |
||
|
24.8.2011 |
Velmetia |
|
EU/1/08/456/001-016 |
30.8.2011 |
||
|
24.8.2011 |
Vfend |
|
EU/1/02/212/001-026 |
30.8.2011 |
||
|
24.8.2011 |
ViraferonPeg |
|
EU/1/00/132/001-050 |
30.8.2011 |
||
|
24.8.2011 |
Yttriga |
|
EU/1/05/322/001-002 |
29.8.2011 |
||
|
24.8.2011 |
Zevalin |
|
EU/1/03/264/001 |
30.8.2011 |
||
|
24.8.2011 |
Zometa |
|
EU/1/01/176/001-009 |
30.8.2011 |
||
|
26.8.2011 |
Alisade |
|
EU/1/08/474/001-003 |
31.8.2011 |
||
|
26.8.2011 |
Avamys |
|
EU/1/07/434/001-003 |
31.8.2011 |
||
|
26.8.2011 |
Cervarix |
|
EU/1/07/419/001-012 |
31.8.2011 |
||
|
26.8.2011 |
Corlentor |
|
EU/1/05/317/001-014 |
31.8.2011 |
||
|
26.8.2011 |
Fertavid |
|
EU/1/09/510/001-019 |
31.8.2011 |
||
|
26.8.2011 |
HBVAXPRO |
|
EU/1/01/183/001 EU/1/01/183/004-005 EU/1/01/183/007-008 EU/1/01/183/011 EU/1/01/183/013 EU/1/01/183/015 EU/1/01/183/018-032 |
31.8.2011 |
||
|
26.8.2011 |
Insulin Human Winthrop |
|
EU/1/06/368/001-168 |
31.8.2011 |
||
|
26.8.2011 |
Procoralan |
|
EU/1/05/316/001-014 |
31.8.2011 |
||
|
26.8.2011 |
Prolia |
|
EU/1/10/618/001-004 |
31.8.2011 |
||
|
26.8.2011 |
Sebivo |
|
EU/1/07/388/001-003 |
31.8.2011 |
||
|
26.8.2011 |
Tepadina |
|
EU/1/10/622/001-002 |
31.8.2011 |
||
|
26.8.2011 |
Topotecan Teva |
|
EU/1/09/552/001-004 |
31.8.2011 |
— Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (2) ): Accepted
|
Date of the Décision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
||
|
5.8.2011 |
Proteq West Nile |
West Nile recombinant canarypox virus (vCP2017 virus) |
|
EU/2/11/129/001-004 |
Suspension for injection |
QI05AX |
10.8.2011 |
||
|
5.8.2011 |
Zulvac 1 Bovis |
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP ≥ 1 |
|
EU/2/11/130/001-003 |
Suspension for injection |
QI02AA08 |
10.8.2011 |
||
|
5.8.2011 |
Zulvac 1 Ovis |
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP ≥ 1 |
|
EU/2/11/131/001-006 |
Suspension for injection |
QI04AA02 |
10.8.2011 |
||
|
18.8.2011 |
Emdocam |
Meloxicam |
|
EU/2/11/128/001-003 |
Solution for injection |
QM01AC06 |
22.8.2011 |
— Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
||
|
7.7.2011 |
Leucofeligen FeLV/RCP |
|
EU/2/09/097/001-002 |
11.7.2011 |
||
|
7.7.2011 |
Palladia |
|
EU/2/09/100/001-003 |
12.7.2011 |
||
|
7.7.2011 |
ProMeris Duo |
|
EU/2/06/065/001-010 |
11.7.2011 |
||
|
11.7.2011 |
Trocoxil |
|
EU/2/08/084/001-005 |
13.7.2011 |
||
|
13.7.2011 |
Loxicom |
|
EU/2/08/090/001-018 |
18.7.2011 |
||
|
20.7.2011 |
Posatex |
|
EU/2/08/081/001-003 |
25.7.2011 |
||
|
27.7.2011 |
Poulvac FluFend H5N3 RG |
|
EU/2/06/060/001-002 |
1.8.2011 |
||
|
27.7.2011 |
ProMeris |
|
EU/2/06/064/001-004 |
1.8.2011 |
||
|
27.7.2011 |
Slentrol |
|
EU/2/07/071/001-003 |
2.8.2011 |
||
|
5.8.2011 |
Cerenia |
|
EU/2/06/062/001-005 |
10.8.2011 |
||
|
5.8.2011 |
Virbagen Omega |
|
EU/2/01/030/001-004 |
10.8.2011 |
||
|
19.8.2011 |
Nobilis Influenza H5N2 |
|
EU/2/06/061/001-004 |
23.8.2011 |
||
|
19.8.2011 |
Zolvix |
|
EU/2/09/101/001-010 |
23.8.2011 |
||
|
24.8.2011 |
Suvaxyn Aujeszky 783 +O/W |
|
EU/2/98/009/001-006 |
30.8.2011 |
— Withdrawal of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
||
|
10.8.2011 |
Yarvitan |
|
EU/2/06/063/001-003 |
12.8.2011 |
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
|
The European Medicines Agency |
|
7, Westferry Circus, Canary Wharf |
|
UK - LONDON E14 4H |
(1) OJ L 136, 30.4.2004, p. 1.
(2) OJ L 136, 30.4.2004, p. 1.